Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Covance Expands Singapore Central Laboratory

Published: Friday, April 19, 2013
Last Updated: Thursday, April 18, 2013
Bookmark and Share
The expansion doubles genomics footprint, adds anatomic pathology and nutritional chemistry capabilities.

Covance Inc. has announced completion of the expansion of its central laboratory facility in Singapore to enhance the company's current service offerings and position it to meet current and future growth of drug development in the Asia Pacific region.

The expansion is the latest in Covance's continued investment in Singapore, and an important element of the strategic investment plans for the Asia Pacific region that also includes recent growth in operations in China and Japan.

The laboratory, at approximately 2,700 square meters (29,000 square feet), is the largest of its kind in Singapore, providing clinical testing services to clients in Asia, including South Korea, Taiwan, Hong Kong, the Philippines, Australia, and India.

This laboratory expansion doubles the size of Covance's genomics footprint in Singapore, while also adding capabilities in anatomic pathology and nutritional chemistry.

Like Covance's central laboratories in Indianapolis, Indiana; Geneva, Switzerland; Shanghai, China; and Tokyo, Japan, the Singapore facility continues to provide a full-service offering that includes chemistry, immunology, hematology, flow cytometry, genomics, anatomic pathology, and microbiology.

"For the last 13 years Covance has provided central laboratory testing services in Singapore, where we have seen increasing demand for efficient, high-quality clinical trial data and support," said Jon Koch, Corporate Vice President and Global General Manager, Central Laboratory Services, Covance.

Koch continued, "This expansion will help us better serve both our local and multinational customers' R&D needs in key therapeutic areas like oncology and metabolic diseases while reflecting Covance's continued commitment to the Asia Pacific region."

"Covance's expansion reaffirms Singapore's proposition as a strategic location for CROs to base their regional operations as they expand to tap on the fast growing opportunities in Asia," said Kevin Lai, Director, Biomedical Sciences Group, from the Economic Development Board of Singapore.

Lai continued, "Its investment is a strong vote of confidence in our efforts in developing Singapore as a leading biomedical sciences hub with strong capabilities to support translational and clinical research."

"In addition to providing our clients in Asia the broadest access to clinical trial testing services, Covance's facilities in the Asia Pacific region also offer preclinical services together with a comprehensive range of clinical development services to support both regional and global trials. Being the only CRO with the expertise to develop a molecule from discovery through all preclinical and clinical milestones makes Covance a preferred provider for companies wishing to develop drug candidates in Asia and around the globe," added Deborah Keller, Executive Vice President and Group President, R&D Laboratories, Covance.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!